Published in Haematologica on February 12, 2013
Megakaryocytes contribute to the bone marrow-matrix environment by expressing fibronectin, type IV collagen, and laminin. Stem Cells (2014) 0.98
Enhanced expression of Stim, Orai, and TRPC transcripts and proteins in endothelial progenitor cells isolated from patients with primary myelofibrosis. PLoS One (2014) 0.93
The importance of calcium in the regulation of megakaryocyte function. Haematologica (2014) 0.87
Dynamin 2-dependent endocytosis is required for normal megakaryocyte development in mice. Blood (2014) 0.82
The secret life of a megakaryocyte: emerging roles in bone marrow homeostasis control. Cell Mol Life Sci (2015) 0.78
Pathophysiological Significance of Store-Operated Calcium Entry in Megakaryocyte Function: Opening New Paths for Understanding the Role of Calcium in Thrombopoiesis. Int J Mol Sci (2016) 0.75
Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms. Mediators Inflamm (2015) 0.75
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood (2009) 23.52
Transcriptional control by the TGF-beta/Smad signaling system. EMBO J (2000) 8.49
Non-Smad pathways in TGF-beta signaling. Cell Res (2009) 5.54
Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1. Cell Stem Cell (2010) 3.69
The biogenesis of platelets from megakaryocyte proplatelets. J Clin Invest (2005) 2.30
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood (2007) 2.09
Autocrine transforming growth factor-beta regulation of hematopoiesis: many outcomes that depend on the context. Oncogene (2005) 1.29
Determinants of platelet number and regulation of thrombopoiesis. Hematology Am Soc Hematol Educ Program (2009) 1.28
Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor. Blood (2002) 1.25
In vitro megakaryocyte differentiation and proplatelet formation in Ph-negative classical myeloproliferative neoplasms: distinct patterns in the different clinical phenotypes. PLoS One (2011) 1.15
TGF-beta1 induces bone marrow reticulin fibrosis in hairy cell leukemia. J Clin Invest (2004) 1.08
Decrease of Smad4 gene expression in patients with essential thrombocythaemia may cause an escape from suppression of megakaryopoiesis by transforming growth factor-beta1. Br J Haematol (2004) 1.04
Constitutively released adenosine diphosphate regulates proplatelet formation by human megakaryocytes. Haematologica (2012) 0.90
Selective regulation of the activity of different hematopoietic regulatory proteins by transforming growth factor beta 1 in normal and leukemic myeloid cells. Blood (1990) 0.89
Autocrine role of angiopoietins during megakaryocytic differentiation. PLoS One (2012) 0.81
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med (2012) 10.07
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood (2008) 7.73
Silk-based biomaterials. Biomaterials (2003) 7.72
Mechanism of silk processing in insects and spiders. Nature (2003) 4.85
Dissolvable films of silk fibroin for ultrathin conformal bio-integrated electronics. Nat Mater (2010) 4.62
Silk as a Biomaterial. Prog Polym Sci (2007) 4.13
New opportunities for an ancient material. Science (2010) 3.95
Three-dimensional aqueous-derived biomaterial scaffolds from silk fibroin. Biomaterials (2005) 3.87
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol (2011) 3.83
In vitro degradation of silk fibroin. Biomaterials (2005) 3.56
Materials fabrication from Bombyx mori silk fibroin. Nat Protoc (2011) 3.45
In vivo degradation of three-dimensional silk fibroin scaffolds. Biomaterials (2008) 3.39
Electrospun silk-BMP-2 scaffolds for bone tissue engineering. Biomaterials (2006) 3.27
Villification: how the gut gets its villi. Science (2013) 2.94
Stem cell-based tissue engineering with silk biomaterials. Biomaterials (2006) 2.88
The inflammatory responses to silk films in vitro and in vivo. Biomaterials (2005) 2.79
Porous 3-D scaffolds from regenerated silk fibroin. Biomacromolecules (2004) 2.77
Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology (2006) 2.72
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood (2013) 2.60
Cell differentiation by mechanical stress. FASEB J (2001) 2.56
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood (2007) 2.53
Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood (2004) 2.52
Structure and properties of silk hydrogels. Biomacromolecules (2004) 2.50
A physically transient form of silicon electronics. Science (2012) 2.47
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood (2007) 2.41
Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2007) 2.33
Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica (2004) 2.32
Clinical correlates in an experimental model of repetitive mild brain injury. Ann Neurol (2013) 2.32
Vascularization strategies for tissue engineering. Tissue Eng Part B Rev (2009) 2.31
Regulation of silk material structure by temperature-controlled water vapor annealing. Biomacromolecules (2011) 2.24
Congenital amegakaryocytic thrombocytopenia: clinical and biological consequences of five novel mutations. Haematologica (2007) 2.23
Silk matrix for tissue engineered anterior cruciate ligaments. Biomaterials (2002) 2.22
Electrospinning Bombyx mori silk with poly(ethylene oxide). Biomacromolecules (2002) 2.20
Waterproof AlInGaP optoelectronics on stretchable substrates with applications in biomedicine and robotics. Nat Mater (2010) 2.20
Sonication-induced gelation of silk fibroin for cell encapsulation. Biomaterials (2007) 2.15
Engineering adipose-like tissue in vitro and in vivo utilizing human bone marrow and adipose-derived mesenchymal stem cells with silk fibroin 3D scaffolds. Biomaterials (2007) 2.13
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood (2007) 2.09
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood (2008) 2.09
Macrophage responses to silk. Biomaterials (2003) 2.04
In vitro cartilage tissue engineering with 3D porous aqueous-derived silk scaffolds and mesenchymal stem cells. Biomaterials (2005) 2.02
Influence of macroporous protein scaffolds on bone tissue engineering from bone marrow stem cells. Biomaterials (2005) 1.94
Engineering bone-like tissue in vitro using human bone marrow stem cells and silk scaffolds. J Biomed Mater Res A (2004) 1.94
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood (2011) 1.93
Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis. Lancet (2005) 1.93
Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation (2003) 1.93
Circulating endothelial progenitor cells in preterm infants with bronchopulmonary dysplasia. Am J Respir Crit Care Med (2009) 1.92
Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica (2002) 1.91
Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol (2009) 1.88
Water-insoluble silk films with silk I structure. Acta Biomater (2009) 1.85
Silk microspheres for encapsulation and controlled release. J Control Release (2006) 1.81
Bioactive silk protein biomaterial systems for optical devices. Biomacromolecules (2008) 1.79
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood (2009) 1.78
Growth factor gradients via microsphere delivery in biopolymer scaffolds for osteochondral tissue engineering. J Control Release (2008) 1.72
Biomaterial films of Bombyx mori silk fibroin with poly(ethylene oxide). Biomacromolecules (2004) 1.70
Ultra-sensitive vibrational spectroscopy of protein monolayers with plasmonic nanoantenna arrays. Proc Natl Acad Sci U S A (2009) 1.69
Twenty-one millisecond pulsars in Terzan 5 using the Green Bank Telescope. Science (2005) 1.68
Porous silk fibroin 3-D scaffolds for delivery of bone morphogenetic protein-2 in vitro and in vivo. J Biomed Mater Res A (2006) 1.68
Human bone marrow stromal cell responses on electrospun silk fibroin mats. Biomaterials (2004) 1.67
Cartilage tissue engineering with silk scaffolds and human articular chondrocytes. Biomaterials (2006) 1.67
Role of membrane potential in the regulation of cell proliferation and differentiation. Stem Cell Rev (2009) 1.66
The May-Hegglin anomaly gene MYH9 is a negative regulator of platelet biogenesis modulated by the Rho-ROCK pathway. Blood (2007) 1.64
Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci U S A (2004) 1.62
Silk fibroin microtubes for blood vessel engineering. Biomaterials (2007) 1.61
Human bone marrow-derived MSCs can home to orthotopic breast cancer tumors and promote bone metastasis. Cancer Res (2010) 1.61
Silk nanospheres and microspheres from silk/pva blend films for drug delivery. Biomaterials (2009) 1.59
Modification of silk fibroin using diazonium coupling chemistry and the effects on hMSC proliferation and differentiation. Biomaterials (2008) 1.59
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol (2012) 1.58
Silk film biomaterials for cornea tissue engineering. Biomaterials (2008) 1.58
Silk polymer-based adenosine release: therapeutic potential for epilepsy. Biomaterials (2008) 1.57
Control of in vitro tissue-engineered bone-like structures using human mesenchymal stem cells and porous silk scaffolds. Biomaterials (2006) 1.56
Silk-based electrospun tubular scaffolds for tissue-engineered vascular grafts. J Biomater Sci Polym Ed (2008) 1.55
Early haemoglobin-independent increase of plasma erythropoietin levels in patients with acute myocardial infarction. Eur Heart J (2007) 1.55
Polymorphisms in the osteopontin promoter affect its transcriptional activity. Physiol Genomics (2004) 1.54
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica (2008) 1.54
Mapping domain structures in silks from insects and spiders related to protein assembly. J Mol Biol (2004) 1.53
Two-photon microscopy for non-invasive, quantitative monitoring of stem cell differentiation. PLoS One (2010) 1.52
Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol (2007) 1.52
Electrospun silk biomaterial scaffolds for regenerative medicine. Adv Drug Deliv Rev (2009) 1.52
In vitro evaluation of electrospun silk fibroin scaffolds for vascular cell growth. Biomaterials (2008) 1.51
Native-sized recombinant spider silk protein produced in metabolically engineered Escherichia coli results in a strong fiber. Proc Natl Acad Sci U S A (2010) 1.51
Vortex-induced injectable silk fibroin hydrogels. Biophys J (2009) 1.50
Role of adult mesenchymal stem cells in bone tissue engineering applications: current status and future prospects. Tissue Eng (2005) 1.50
Consensus conference on the management of tumor lysis syndrome. Haematologica (2008) 1.49
Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood (2012) 1.48